PTC Therapeutics Inc（PTCT）の財務PTCTPTC Therapeutics Inc

PTC Therapeutics, Inc. (PTCT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Sephience, accounting for 63.4% of total sales, equivalent to $151.31M. Other significant revenue streams include Translarna and Emflaza. Understanding this composition is critical for investors evaluating how PTCT navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, PTC Therapeutics, Inc. maintains a gross margin of 91.19%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 41.32%, while the net margin is 23.16%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively PTCT converts its operational activities into shareholder value.

In the context of the broader market, PTCT competes directly with industry leaders such as XENE and GRFS. With a market capitalization of $5.98B, it holds a significant position in the sector. When comparing efficiency, PTCT's gross margin of 91.19% stands against XENE's N/A and GRFS's 37.57%. Such benchmarking helps identify whether PTC Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

The company reported a significant revenue increase in Q2 2026, achieving $360.5 million, which is a 101.5% increase year-over-year. The gross margin for Q2 was 91.19%, indicating strong profitability on sales. However, the net income remains volatile, with a recent net income of $83.5 million in Q2 2026, showcasing potential for recovery.